by Gerald Tracy, KOMONews.com Digital Producer
The vaccine, called GPB510, was developed at the UW School of Medicine along with SK bioscience, which is leading the clinical development. The two are seeking South Korea authorization for use within a month.
Development started when Seattle scientists looked to create a second-generation COVID-19 vaccine. The vaccine would be effective at low doses, safe, simple to make on a large scale and stable without deep freezing.
GPB510, fully approved by regulators, will be available through COVAX and South Korea has agreed to buy 10 million doses and UW said it is licensing the technology royalty-free throughout the pandemic.
Learn more from UW Medicine Newsroom:
UW Medicine-developed COVID vaccine effective in test
A Phase 3 clinical trial found that the second-generation vaccine generates high levels of neutralizing antibodies.
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2, Cell, Volume 183, Issue 5, 25 November 2020, Pages 1367-1382.e17
Experimental Model and Subject Details
